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Glucose challenge metabolomics 
implicates medium-chain 
acylcarnitines in insulin resistance
Christoph Nowak1,2, Susanne Hetty1, Samira Salihovic1, Casimiro Castillejo-Lopez1,  
Andrea Ganna3,4,5,6, Naomi L. Cook  1, Corey D. Broeckling7, Jessica E. Prenni7, Xia Shen6,8, 
Vilmantas Giedraitis  9, Johan Ärnlöv2,10, Lars Lind11, Christian Berne12, Johan Sundström11, 
Tove Fall  1 & Erik Ingelsson1,13,14
Insulin resistance (IR) predisposes to type 2 diabetes and cardiovascular disease but its causes are 
incompletely understood. Metabolic challenges like the oral glucose tolerance test (OGTT) can 
reveal pathogenic mechanisms. We aimed to discover associations of IR with metabolite trajectories 
during OGTT. In 470 non-diabetic men (age 70.6 ± 0.6 years), plasma samples obtained at 0, 30 and 
120 minutes during an OGTT were analyzed by untargeted liquid chromatography-mass spectrometry 
metabolomics. IR was assessed with the hyperinsulinemic-euglycemic clamp method. We applied 
age-adjusted linear regression to identify metabolites whose concentration change was related to IR. 
Nine trajectories, including monounsaturated fatty acids, lysophosphatidylethanolamines and a bile 
acid, were significantly associated with IR, with the strongest associations observed for medium-chain 
acylcarnitines C10 and C12, and no associations with L-carnitine or C2-, C8-, C14- or C16-carnitine. 
Concentrations of C10- and C12-carnitine decreased during OGTT with a blunted decline in participants 
with worse insulin resistance. Associations persisted after adjustment for obesity, fasting insulin and 
fasting glucose. In mouse 3T3-L1 adipocytes exposed to different acylcarnitines, we observed blunted 
insulin-stimulated glucose uptake after treatment with C10- or C12-carnitine. In conclusion, our results 
identify medium-chain acylcarnitines as possible contributors to IR.
Impaired responsiveness to insulin, insulin resistance (IR), can lead to type 2 diabetes (T2D)1,2, myocardial infarc-
tion and stroke3,4. The pathophysiology of IR is incompletely understood and the rising global number of persons 
at risk of T2D and cardiovascular disease (CVD) due to IR demands new insights for prevention and treatment. 
Metabolic challenges, like the oral glucose tolerance test (OGTT), can reveal early pathogenic mechanisms of IR 
not apparent in fasting assessment5–8.
Untargeted plasma metabolomics quantifies a broad spectrum of small (<1,500 Da) circulating molecules and 
captures an integrative perspective of genomic, post-transcriptional and environmental effects9. Metabolomics 
1Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, 
Uppsala, Sweden. 2Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Huddinge, 
Sweden. 3Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, United States 
of America. 4Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, 
MA, United States of America. 5Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, 
Cambridge, MA, United States of America. 6Department of Medical Epidemiology and Biostatistics, Karolinska 
Institutet, Stockholm, Sweden. 7Proteomics and Metabolomics Facility, Colorado State University, Fort Collins, 
CO, United States of America. 8Centre for Global Health Research, Usher Institute of Population Health Sciences 
and Informatics, University of Edinburgh, Edinburgh, UK. 9Department of Public Health and Caring Sciences, 
Geriatrics, Uppsala University, Uppsala, Sweden. 10School of Health and Social Studies, Dalarna University, Falun, 
Sweden. 11Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Uppsala, Sweden. 
12Department of Medical Sciences, Clinical Diabetology and Metabolism, Uppsala University, Uppsala, Sweden. 
13Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, 
CA, United States of America. 14Stanford Cardiovascular Institute, Stanford University, Stanford, CA, 94305, USA. 
Tove Fall and Erik Ingelsson contributed equally to this work. Correspondence and requests for materials should be 
addressed to E.I. (email: eriking@stanford.edu)
Received: 14 December 2017
Accepted: 17 May 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIFIC RePoRTs |  (2018) 8:8691  | DOI:10.1038/s41598-018-26701-0
has been used to discover fasting biomarkers for IR10 and T2D11, and has highlighted metabolic challenge profiles 
in small studies of healthy adults5,6. Using ultraperformance liquid chromatography-time-of-flight mass spec-
trometry (UPLC-TOF-MS) in fasting plasma from individuals from the general population, we previously found 
evidence for a causal effect of IR on monounsaturated fatty acid (FA) concentrations12, and for shared genetic 
origins between T2D and the metabolism of bile acids and phospholipids13.
Studying the challenged metabolic state is important, as insulin acts mainly in the post-prandial state and 
metabolic abnormalities could be masked in the fasting state. There is, however, a lack of human studies com-
bining a metabolic challenge with repeated plasma metabolomics and gold standard assessment of IR, such 
as the hyperinsulinemic-euglycemic clamp (HEC) method. Ho and colleagues7 measured 110 metabolites in 
pre-/post-OGTT plasma in 377 non-diabetic persons, but used the fasting surrogate measure homeosta-
sis model assessment IR14 to dichotomize the continuous trait IR. They found blunted excursions in lactate, 
β-hydroxybutyrate, isoleucine and pyridoxate in insulin resistant individuals, but did not study acylcarnitines 
or FA subtypes.
Here, we combine plasma metabolomics at three time-points during an OGTT (reflecting metabolite trajectories 
post glucose challenge) with HEC assessment (on a separate day, reflecting whole-body insulin sensitivity in steady 
state) in 470 non-diabetic 71-year-old Europeans to identify metabolite trajectories associated with IR, followed by 
studies in adipocytes. To our knowledge, this is the largest study combining these unique techniques to date.
Materials and Methods
Study approval. All participants provided written informed consent. The study was approved by the 
Regional Ethical Review Board of Uppsala University (251/90) and has been carried out in according with the 
principles of the Declaration of Helsinki as revised in 2008.
Study population. The Uppsala Longitudinal Study of Adult Men (ULSAM) was initiated in 1970–1973 
and enrolled 2,322 (81.7%) of all 2,841 men born between 1920–1924 and resident in Uppsala county, Sweden15. 
Biochemical and medical assessment at baseline and repeat assessments have been detailed online (http://www.
pubcare.uu.se/ulsam/) and described previously16. The current study used data and biological samples obtained 
at the age of 71 years between August 1991 and May 1995. At this examination, the participants underwent an 
OGTT and HEC assessment. Due to an unfortunate freezer failure in the early 2000s, about half of the stored 
biological samples were lost. For the present study, we performed untargeted metabolomics in all individuals with 
remaining samples from the 0 min, 30 min and 120 min time points of the OGTT. Out of n = 626 individuals with 
OGTT metabolomics data, n = 548 individuals were included after removal of individuals with missing data for 
HEC and/or samples that failed metabolomics quality control. Another 78 participants were excluded because of 
prevalent T2D, defined as follows: self-reported diagnosis of diabetes, previous diagnosis of T2D in the Swedish 
Hospital Discharge Register (International Classification of Diseases [ICD] codes, 250.00 or 250.02 [ICD-9] or 
E11 [ICD-10]), prescription of insulin/anti-diabetic medication (Anatomical Therapeutic Chemical code, A10), 
fasting plasma glucose ≥7 mmol/L (126 mg/dL), or 2h-OGTT plasma glucose ≥11 mmol/L (198 mg/dL). After 
these exclusions, 470 individuals were eligible for the present investigation (Supplementary Fig. 1).
OGTT and blood sampling. Overnight fasted (>8 h) individuals underwent standard 75 g oral glucose 
solution OGTT with venous blood sampling in EDTA tubes at baseline, 30 min, 60 min, 90 min and 120 min. 
A portion of each sample was spun down, stored on ice for a maximum of 4 h, and stored as plasma samples at 
-70 °C until analysis. For the purpose of the present study, we performed untargeted metabolomics in samples 
from three of the time points: 0 min, 30 min and 120 min.
HEC. The method by DeFronzo et al.17 was modified with a slightly higher insulin infusion dose (56mU/
min per body surface area, where DeFronzo et al. used 40 mU) to more thoroughly suppress hepatic glucone-
ogenesis18 and carried out separate from OGTT after about one week. Participants were instructed to attend 
after an overnight fast and all participants were assessed with the same clamp protocol at Uppsala University 
Hospital. No standardized meal was prepared on the day before the clamp procedure. Following placement on 
a warmed blanket, intravenous cannulation of the preferred forearm was performed in the antecubital fossa for 
infusions and the dorsum of the hand for blood sampling. After 40 min of rest, a baseline blood sample was 
taken and a bolus injection of semisynthetic human insulin was given over 10 min, followed by continuous infu-
sion (56 mU × min−1 × m2 × body surface area−1) for 110 min. Steady-state glycemia of 5.1 mmol/L (91.8 mg/
dL) was achieved by titration of a 20% glucose infusion and GlucAnalyzer readings every 5 min. Steady-state 
estimates were obtained as the mean value between 60–120 min and the glucose disposal index M was derived 
as the amount of glucose taken up during the 60 min of the stead-state condition. The insulin sensitivity index 
M/I (mg × kg−1 × kg × body weight−1 × min−1 per mU/L × 100) was calculated by dividing the glucose disposal 
index M by the mean insulin concentration during the corresponding period. The M/I index thus represents 
a measure of tissue sensitivity to insulin per unit of insulin, i.e. the amount of glucose metabolized per unit of 
insulin. The Pearson correlation coefficient between glucose disposal (M value) and the M/I index was 0.93 in 
our study sample. In secondary analyses, we replicated top associations using M value instead of M/I as outcome 
(Supplementary Methods). Estimating total body insulin sensitivity in the described setting assumes complete 
suppression of endogenous glucose production; and under euglycemic condition, about 90% of hepatic glucose 
production is suppressed by increasing insulin concentrations to 60 mU/L18.
UPLC-TOF-MS. Venous blood samples collected in 1991–1995 were kept on ice for a maximum of 4 h, 
spun down and stored as EDTA plasma samples for ~20 years at -70 °C. The time delay was inevitable as the 
metabolomics methods used in this study only became available in the 2000s and biobank samples were used 
for analysis. Signal processing and statistical analyses were adjusted for storage time as explained below. Thawed 
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EDTA plasma samples were protein-precipitated in methanol and analyzed on a Waters Acquity UPLC and Xevo 
G2-TOF spectrometer. Data were acquired at 5 Hz in positive electrospray ion mode at 6 V and 15–30 V with m/z 
range 50–1,200. Data processing by XCMS is detailed in the Supplementary Materials and (https://github.com/
andgan/metabolomics_pipeline)19. A total of 10,162 features were detected, outliers removed, and features were 
annotated by matching retention time and m/z to in-house standards or public reference libraries according to 
Metabolomics Standard Initiative guidelines19. Signals were adjusted for factors of unwanted variability (retention 
time shift, analysis date, sample collection and plate effect) by ANOVA-type normalization. Metabolomics data 
are available in Metabolights, accession number MTBLS124 (http://www.ebi.ac.uk/metabolights/).
Statistical analysis of human data. Log2-scaled metabolite signal intensities (Met) were analyzed 
by linear regression as follows: First, M/I = Met0 + Met30 + Met120 + age, was tested against M/I = age, by 
ANOVA likelihood ratio test, and metabolites that explained more variation in IR than the age-only model at 
P < 2.6 × 10−4 (Bonferroni-correction for 192 comparisons) were taken forward. Second, for metabolites taken 
forward from step one, M/I = Δ(Met0 - Met30) + Δ(Met30 - Met120) + age, was tested at P < 1.4 × 10−3 (35 com-
parisons) for associations between change in plasma signal intensity during OGTT and IR. Supplementary 
Fig. 1 illustrates a summary of the methods. We ascertained normal distributions in histograms, QQ-plots and 
residual-against-fitted-value plots. Outliers and leverage were assessed in boxplots and plots of Cook’s distance 
and studentized residuals. All models additionally adjusted for sample quality as metabolomics analysis was per-
formed after a ~20 yr delay between sampling in the 1990s and UPLC-TOF-MS analysis in the 2010s when the 
new technology became available. It has been shown that freezer storage time and freezing cycles can affect 
metabolite measurements20 and we accounted for these factors of unwanted variability as follows: Biobank log-
books for deep-frozen plasma covering the entire storage period were scrutinized for entries on sample quality or 
freezing cycles and analyses were adjusted by storage time in days, comments indicating possible previous thaw-
ing and re-freezing (dummy variable, 122 of 470 samples included in the present study; 26%) and any logbook 
comments querying possible hemolysis (dummy variable, 8 of 470 samples, 2.7%). The study was underpowered 
to assess associations in the 78 persons with prevalent T2D who were excluded.
Murine 3T3-L1 preadipocyte culture and differentiation. The mouse preadipocyte line 3T3-L1 
was obtained from ATCC and cultured according to the manufacturer’s instructions in high glucose (4.5 g/L) 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen; Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin. Differentiation was initiated in 48 h 
post-confluent cells plated on 24- or 96-well plates for lipolysis and glucose uptake assays, respectively, with 
0.5 mM 3-isobutyl-1-methylxanthine (Sigma), 0.5 μM dexamethasone (Sigma), and 1.25 μM human insulin 
(Sigma) in DMEM-10%-FBS. After 2 d, the differentiation medium was replaced with DMEM-10%-FBS sup-
plemented by 1 μg/mL insulin for another 2 d. Thereafter, cells were maintained in DMEM-10%-FBS that was 
replaced every 2 d. Experiments were performed 10–14 d after differentiation initiation. The degree of differ-
entiation was close to 100% for all experiments and did not differ between wells within plates. For experiments, 
overnight serum-starved, fully differentiated adipocytes were used.
Tests for cell culture contamination. We excluded contamination by mycoplasma through Hoechst indi-
rect DNA staining of the starter culture used for all experiments. Mycoplasma contamination thereafter would 
also have been detected, since all experimental wells were Hoechst-stained and imaged using the DAPI fluores-
cence microscopy channel following glucose uptake and lipolysis testing in order to count cell nuclei. Bacterial 
Trait
M/IA 5.3 ± 2.4
Fasting glucose (mmol/L) 5.4 ± 0.6
Fasting insulin (mU/L) 13.6 ± 6.6
OGTT glucose (AUC) 56.0 ± 30.0
OGTT insulin (AUC) 1225.9 ± 749.5
Current smokerB 20.1%
At least moderate physical activity 88.3%
BMI (kg/m2) 26.0 ± 3.3
Waist circumference (cm) 93.2 ± 9.5
Systolic BP (mmHg) 144 ± 19
Diastolic BP (mmHg) 82 ± 10
Antihypertensive medication 30.2%
Serum triglycerides (mmol/L) 1.4 ± 0.7
Total serum cholesterol (mmol/L) 5.9 ± 1.0
HDL-cholesterol (mmol/L) 1.3 ± 0.4
Lipid medicationB 10.2%
C-reactive protein (mg/L) 3.3 ± 4.7
Table 1. Characteristics of 470 non-diabetic men included in the present study (mean ± SD or proportion). 
AHEC M/I in mg × kg−1 × kg BW−1 × min−1 per mU/L × 100. BMissing responses (3.3% for smoking, 1.7% for 
lipid medication) counted as “no”.
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and fungal contamination was excluded visually by inspecting different levels of the supernatant in each well by 
light microscopy.
Glucose uptake assay. Insulin-stimulated glucose uptake was measured as previously described21 using the 
fluorescently labeled glucose analog 2-deoxy-2-[(7-nitro-2,1,3-benzoxadizol-4-yl) amino]-D-glucose (2-NBDG) 
(Thermo Fisher) in fully differentiated 3T3-L1 cells plated on black 96-well plates with clear bottoms (Corning). 
3T3-L1 adipocytes were serum-starved overnight in high-glucose DMEM (4.5 g/L). Cells were pre-incubated 
with or without different acylcarnitines (100 µM) for 2 h. After the first hour of incubation, cells were washed 
twice with PBS and glucose-starved for another hour in glucose-free DMEM using the same acylcarnitine treat-
ments. This was followed by 20 min incubation with or without insulin (100 nM) at 37 °C in 100 μL DMEM (1 g/L 
glucose) containing 100 μg/mL 2-NBDG. Cells were then washed three times in 150 μL phosphate-buffered saline 
(PBS) before addition of 100 μL PBS containing Hoechst nuclear staining solution (Thermo Fisher) at a final 
concentration of 1.83 μL/mL. Intracellular fluorescence was quantified by computer-assisted microscopy (EVOS 
FL Auto Cell Imaging System, Life Technologies) using the GFP channel for 2-NBDG fluorescence intensity and 
the DAPI channel to image Hoechst-stained cell nuclei. Microscopy images (10 × magnification, 16 images/well) 
were saved and exported for analysis using in-house scripts in CellProfiler (v2.2.0)22 and Python. Analysis scripts 
are available on request. In brief, the software identifies individual cells in each image, quantifies the difference in 
fluorescence signal in cells compared to the background, and calculates average intracellular fluorescence signals 
adjusted for the number of cells per image. Experiments in n = 3 wells were performed in replicates.
Lipolysis assay. Differentiated, overnight serum-starved 3T3-L1 adipocytes were pre-incubated in 
high-glucose DMEM (4.5 g/L) with 2% fatty acid-free BSA containing 100 µM of different acylcarnitines 
(acetyl-DL-carnitine HCL (C2), decanoyl-L-carnitine (C10), lauroyl-L-carnitine (C12) and palmitoyl-L-carnitine 
(C16; all obtained from Sigma), followed by addition of 100 nM isoproterenol with or without 10 nM insulin for 
1 h. Free glycerol levels present in the medium were determined using a colorimetric kit (Free Glycerol reagent; 
Sigma-Aldrich) and normalized to cell density. In short, 20 μL medium/well was mixed with 100 μL glycerol 
reagent, incubated for 15 min at room temperature and absorbance measured at OD 540 nm using the Varioskan 
Figure 1. Abundance of plasma metabolites during OGTT according to insulin sensitivity. UPLC-TOF-MS 
signal intensity normalized for factors of unwanted variability is plotted on log2-scale in n = 470 non-diabetic 
men grouped according to quartile of insulin sensitivity (M/I) in boxplots. Quartile 1 (green) represents highest 
IR; quartile 4 (red) the least IR.
www.nature.com/scientificreports/
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LUX multimode microplate reader (Thermo Scientific). Cells were stained with Hoechst nuclear staining solution 
(Thermo Fisher, final concentration 1.83 μL/mL) and cell number/well was quantified using computer-assisted 
microscopy (see ‘Glucose uptake’ for details) for normalization of free glycerol concentration by cell density. 
Experiments in n = 2 wells were performed in triplicates.
Statistical analysis of in vitro results. In vitro glucose uptake and lipolysis results were assessed for 
normality by histogram and Shapiro-Wilk test. This implied no significant aberration from normal distribu-
tion, both for raw data and ANOVA residuals including main effects for treatment (insulin or isoproterenol and 
isoproterenol-insulin for glucose uptake and lipolysis, respectively), condition (acylcarnitines) and interaction 
effects. Two-sample t-tests (two-tailed) were used to compare the effect of added insulin between acylcarnitine 
conditions. Unadjusted P-values are reported. Analyses were performed in R v.3.2.2.
Data availability statement. Full raw metabolomics data are available by open access in the MetaboLights 
archive, accession number MTBLS124 (http://www.ebi.ac.uk/metabolights/). The source code of the metabolom-
ics bioinformatics pipeline is available by open access online (https://github.com/andgan/metabolomics_pipeline/) 
and explained elsewhere18. Individual-level phenotype data from ULSAM are not deposited in the public domain 
as existing ethical permits do not allow this. Full datasets are made available to researchers who meet the criteria 
for confidential data access as stipulated by participant informed consent and institutional review board permis-
sion at Uppsala University. Data access is granted through the Interdisciplinary Collaboration Team on Uppsala 
Longitudinal Studies (ICTUS; http://www.pubcare.uu.se/ulsam/; contact: vilmantas.giedraitis@pubcare.uu.se).
Results
We studied 470 non-diabetic European men (age, 70.6 ± 0.6 yr, Table 1) who underwent HEC assessment and 
2-h-OGTT with blood sampling at 0 min, 30 min and 120 min (Supplementary Fig. 1) on separate days (about one 
week apart). Untargeted UPLC-TOF-MS plasma analysis and processing through an in-house open-access bio-
informatics pipeline19 enabled annotation of 192 metabolites included in the present study. We applied age- and 
Figure 2. Abundance of plasma acylcarnitines during OGTT according to insulin sensitivity. (A) Log2-scaled, 
normalized UPLC-TOF-MS signal intensity of detected carnitine species according to quartile of insulin 
sensitivity (M/I) in boxplots (n = 470). (B) Difference in signal change 30–120 min between highest IR (M/I 
quartile 1, n = 117) and lowest IR (M/I quartile 4, n = 117) for different acylcarnitines.
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sample quality-adjusted linear regression with HEC M/I ratio (glucose disposal per unit of infused insulin) as 
outcome. First, we discovered 35 metabolites that were associated with IR at the Bonferroni-adjusted significance 
level in linear models combining all three time-points during OGTT. These included seven glycerophospho-
lipids, six glycerolipids, four glycerophosphoethanolamines, six unsaturated FAs, four acylcarnitines, two bile 
acids, and one each of monosaccharides, peptides, saturated FA, steroids, imidazopyrimidine and propranolol 
(Supplementary Fig. 1). The regression results for all 35 out of 192 tested metabolites that were significantly 
associated with IR at either one or several time points are listed in Supplementary Table 1. Second, we studied 
associations between M/I and trajectories of these 35 metabolites (Δ0–30 min and Δ30–120 min) and iden-
tified nine trajectories associated at the Bonferroni-adjusted level (listed in Supplementary Table 2). In order 
to illustrate the complex associations, we depict in Fig. 1 the metabolite levels during OGTT according to M/I 
quartile. The declines of oleate, palmitoleate, C10-carnitine and C12-carnitine levels were blunted in individuals 
with IR. Lysophosphatidylethanolamine (LysoPE) 18:1, LysoPE 18:2 and LysoPE 20:4 levels showed little change 
during OGTT in the most insulin resistant men, but decreased from higher fasting values in insulin sensitive 
participants. Deoxycholate-glycine levels rose during 0–30 min from a higher baseline in more insulin resistant 
Figure 3. Glucose uptake and lipolysis in murine 3T3-L1 adipocytes. (a,b) Glucose uptake was quantified 
by fluorescent 2-NBD-glucose uptake (100 μg/mL, 20 min incubation with/without 100 nM insulin (Ins)) 
in DMEM (1 g/L glucose) following overnight serum-starvation and 2 h incubation with/without 100 µM 
acylcarnitines (including 1 h in glucose-free DMEM). Intracellular fluorescence is expressed in relation to basal 
uptake in the control cells. Differences in glucose uptake between basal and insulin-stimulated conditions are 
shown in boxplots (a); panel (b) shows individual conditions from the same experiments. (c,d) Lipolysis was 
measured in overnight serum-starved cells in DMEM over 1 h with/without exposure to 100 nM isoproterenol 
(Iso) ± 10 nM Ins. Cells were pre-incubated for 2 h with vehicle or 100 µM acylcarnitines. Cell density-
normalized glycerol release is shown as the difference in glycerol release after insulin stimulation in panel 
(c), individual conditions in the same experiments are shown in panel (d). Experiments were reproduced in 
replicates for glucose uptake (n = 3 experiment) or triplicates for lipolysis (n = 2 per experiment) and combined 
results are shown. P-values are from two-tailed t-tests; error bars indicate standard errors.
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individuals. As expected, hexose (reflecting mainly glucose) levels rose in all subjects and declined to baseline in 
insulin sensitive persons, with a blunted decline to above baseline in IR. Our findings replicate OGTT metabolite 
profiles in 16 healthy adults23, who also showed declines in plasma medium-chain acylcarnitines and monoun-
saturated FAs as well as an early-phase rise in bile acids. We now report that these trajectories are blunted in IR 
in a ~30-fold larger sample.
The strongest associations with IR were observed for trajectories of C10-carnitine (P = 7.0 × 10−7 for Δ30–
120 min) and C12-carnitine (P = 6.2 × 10−8 for Δ30–120 min). Additional adjustment for body mass index, 
fasting plasma glucose and fasting insulin somewhat attenuated these associations with maintained directions 
(Supplementary Table 3), as did additional adjustment for current smoking, physical exercise, alcohol intake 
and diet (daily intake of total energy, fat, protein and carbohydrates over a seven-day period; Supplementary 
Table 4). We assessed whether the associations with acylcarnitines were carbon chain length-specific, as longer 
chain-length has been associated with increasing IR24,25. Figure 2 shows levels of L-carnitine and all acylcarnitines 
that we were able to annotate using our untargeted metabolomics method (C2, C8, C10, C12, C14, C16 and C18, 
i.e. not including, for example, C3 and C5). Whilst all levels declined during OGTT, only C10- and C12-carnitine 
showed a significantly blunted decline in more insulin resistant individuals.
Our findings appeared specific to C10 and C12 chain lengths and a distinct role of medium-chain acylcarni-
tines in IR has been suggested previously25. We therefore hypothesized that medium-chain acylcarnitines might 
impair insulin-stimulated glycemic response. We tested whether exposure to C2-, C10-, C12-, or C16-carnitine 
in murine 3T3-L1 adipocytes would affect insulin-stimulated glucose uptake (ISGU) and lipolysis. Based on the 
human results, we hypothesized that C10 and C12 would blunt insulin response, while short and long-chain 
acylcarnitines would not. Consistent with this hypothesis, we observed a reduction in ISGU after C10- and 
C12-carnitine incubation compared to control. The average (standard error) increase in glucose uptake after 
100 nM insulin exposure was 74 ± 7% (control), 63 ± 20% (C2, P-value compared to control, P = 0.608), 5 ± 17% 
(C10, P = 0.005), 25 ± 21% (C12, P = 0.032), 55 ± 31% (C16, P = 0.641) (Fig. 3a,b). There was a consistent trend 
for impaired inhibition by insulin of isoproterenol-stimulated lipolysis after C10- or C12-carnitine incubation 
(Fig. 3c,d); effect of insulin on isoproterenol-stimulated glycerol release -20 ± 12% (control), -15 ± 12% (C2, 
P = 0.880), +19 ± 6% (C10, P = 0.036), +11 ± 13% (C12, P = 0.133), -18 ± 12% (C16, P = 0.492).
Discussion
Our findings from the largest human sample assessed by OGTT metabolomics and intravenous measurement 
of insulin sensitivity, together with in vitro studies in murine adipocytes suggest a possible role of C10-carnitine 
and C12-carnitine in IR development. We further found significant differences in OGTT trajectories of monoun-
saturated FAs, several even-numbered LysoPEs and a bile acid between persons with more or less IR. Strengths 
of our study include a large sample assessed with these unique techniques, cohort homogeneity (decreasing the 
likelihood of confounding), rigorous quality control, and follow-up in vitro. The validity of our metabolomics 
pipeline is supported by the replication of reported OGTT metabolite trajectories including the overall decline 
of acylcarnitine5,6,23 and the expected association between IR and hexose. In contrast to metabolomics studies 
involving commercial platforms, we have made the data and methods publicly available. Limitations of our study 
include unknown generalizability to women and other age- and ethnic groups, and ~20 yr storage of plasma in 
−70 °C that may have affected measurements20. Validation in primary human adipocytes or skeletal muscle cells 
would have been preferable to the murine 3T3-L1 cell line, especially given the known biology of acylcarnitines. 
However, we did not have such cells available, and the 3T3-L1 adipocyte model is well established as a proxy for 
human IR26,27. Different acylcarnitines may be transported and metabolized differently, and therefore it is some-
what artificial to use the same concentration (100 μmol) in the in vitro studies. However, as there are no prior data 
on acylcarnitines in these systems, we chose this approach to standardize the experiments and to be able to com-
pare results across acylcarnitines. Another limitation inherent to observational studies is the variability between 
participants with regards to diet, exercise and lifestyle factors that make it difficult to reach a precise picture of the 
underlying pathology without impact of potential confounder or reverse causation.
Our study contributes to clarifying the role of acylcarnitines in IR. Previous studies have suggested a par-
ticular role of medium-chain acylcarnitines in IR24,25, and our findings in the largest challenge study of its kind 
support their contribution. The observational link between overweight and IR notwithstanding1, adjustment for 
obesity had little effect on associations.
Plasma acylcarnitines may reflect cytosolic “overspill”, active cellular export, or may contribute to detoxi-
fication28. Our study cannot disentangle the origin and molecular effects of IR-associated acylcarnitines, but 
follow-up studies at the subcellular level may shed light on a possible primary dysfunction in FA oxidation. 
Genetic studies suggest predominant fat deposition in visceral over subcutaneous tissue as a more important 
contributor to IR than whole-body adiposity29,30. Limited sample size precluded us from testing for genetic effects. 
Nonetheless, we believe that our study provides important insights into the interplay between IR and aberrant FA 
oxidation. Even if the combination of human and cell experiments helps towards understanding the underlying 
mechanisms, we cannot definitively establish whether the associations between IR and medium-chain acylcar-
nitines reflect causal effects, incomplete FA oxidation, dysregulated competition between energy substrates, or 
other shared mechanisms.
The outer mitochondrial membrane enzyme carnitine palmitoyltransferase-1 (CPT1) catalyzes the conver-
sion of FA-derived acyl-coenzyme A esters to acylcarnitines that are transported into the mitochondrion by 
carnitine acylcarnitine translocase. The mitochondrial matrix protein CPT2 then converts acylcarnitines back to 
acyl-coenzyme A esters for participation in beta-oxidation. In rodents, inhibition of both the skeletal muscle and 
the liver isoform of CPT1 has shown beneficial effects on insulin resistance31,32. Dysregulation of CPT with sub-
sequent effects on energy production from FAs and impaired feedback regulation of glucose metabolism could 
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underlie our observations on acylcarnitines. Our study cannot identify the molecular mechanisms linking C10 - 
and C12-carnitine to insulin resistance and future research may address these aspects in detail.
Previous small studies have demonstrated that acylcarnitines may contribute to IR through lipotoxicity related 
to dysfunctional beta-oxidation33,34, as well as through pro-inflammatory action35. Raised plasma concentrations 
of medium-chain acylcarnitines have been linked to increased CVD risk regardless of other risk factors, includ-
ing branched chain amino acids and obesity. Interestingly, this association was absent in adults randomized to a 
Mediterranean diet intervention36. Alongside our findings on an adverse role in IR, the available evidence sug-
gests medium-chain acylcarnitines as possible targets for cardiometabolic prevention. Given the protective effects 
of the Mediterranean diet for T2D and suggestive benefits for adverse acylcarnitine profiles36, the Mediterranean 
diet could provide a possible approach and further targeted research on a mediating role of medium-chain acyl-
carnitines for its effects are indicated.
Similarly to medium-chain acylcarnitines, the overall decline in concentrations of the monounsaturated FAs 
palmitoleate and oleate was blunted during the OGTT in persons with worse IR. Palmitoleate and oleate are 
derived from the diet and from endogenous production by the rate-limiting enzyme stearoyl CoA desaturase 1 
(SCD-1)37. We previously reported genetic evidence for a concentration-lowering effect of IR on these two FAs 
in the fasting state and hypothesised a mediating role of SCD-112. In addition to transcriptional regulation, the 
activity of SCD-1 is controlled through enzymatic and product/substrate regulation38. The blunted concentration 
decline of monounsaturated FAs in insulin resistant persons could be the result of reduced sensitivity of SCD-1 
to intracellular signalling or impaired glucose metabolism and hence reduced production of SCD-1-inhibiting 
intermediates. Desensitized intracellular metabolic signalling may also underlie the OGTT trajectory association 
we observed for the bile acid-derivative deoxycholate-glycine, whose level rose in all participants in the early 
phase of the OGTT, albeit from a higher baseline level with a consequently flatter slope in more insulin resistant 
persons. Previous studies have demonstrated associations between elevated fasting concentrations of bile acids in 
the same chemical class as deoxycholate and IR as well as T2D39,40. In fasting samples, we recently confirmed the 
association between raised deoxycholate levels and risk of T2D, and identified a genetic polymorphism in CYPA1 
that was associated with reduced deoxycholate levels, raised LDL-cholesterol and reduced risk of T2D13. The 
findings in the metabolic challenge setting in the present study concur with the notion of an interaction of IR with 
bile acid metabolism predominantly in the fasted state, since OGTT levels rose and plateaued to similar levels in 
persons on both ends of the insulin resistance/insulin sensitivity spectrum. Ideally, however, our findings should 
be validated in human primary cells, in particular in skeletal muscle cells.
Conclusion
In summary, nine out of 192 metabolite profiles were associated with IR, with the strongest signals detected for 
C10- and C12-carnitines, whose overall decline was blunted in more insulin resistant compared to insulin sen-
sitive individuals. In mouse adipocytes, C10- and C12-carnitine incubation reduced insulin-stimulated glucose 
uptake, in line with a possible contributing mechanism for medium-chain acylcarnitines in IR development. In 
conclusion, we found that the decline in plasma levels of medium-chain acylcarnitines during a glucose challenge 
was blunted in IR, and demonstrated limited in vitro evidence for a contributing role of medium-chain acylcarni-
tines in impaired insulin-mediated glucose uptake.
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